In the Press

Zambon acquires Breath Therapeutics for its late-stage lung disease drug

July 26, 2019 - Privately-held Italian pharmaceutical company Zambon will acquire Breath Therapeutics for $160 million in upfront cash and up to another $405 million based on specified regulatory and sales milestones. The deal extends Zambon’s pipeline in severe respiratory diseases with the acquisition of Breath’s late stage drug candidate for the treatment of Bronchiolitis Obliterans syndrome (BOS), a severe progressive lung disease with no approved therapies that affects about 30,000 people globally.

Zambon heading to US market with €500m acquisition

July 26, 2019 - Zambon is set to acquire respiratory company Breath Therapeutics for up to €500m to complement its respiratory pipeline and get access to the US market.

Zambon enters ‘breath-taking’ acquisition deal worth up to $557M; $156M up front

July 26, 2019 - DUBLIN – Zambon SpA is acquiring Breath Therapeutics BV for €140 million (US$155.8 million) up front plus up to €360 million more in regulatory and commercial milestones linked to the progress of Breath's drug-device combo, which is currently in phase III development for bronchiolitis obliterans syndrome (BOS), a fatal form of airway inflammation that can arise in lung transplant recipients.

Zambon acquires Breath Therapeutics to advance inhalation therapy for BOS

July 25, 2019 - Breath Therapeutics' inhalation drug aims to be the first-in-class therapy for Bronchiolitis Obliterans Syndrome approved by the FDA.

Zambon Acquires Breath Therapeutics for Up-to-€500M, Adding to Respiratory Pipeline

July 25, 2019 - Italian pharma Zambon said today it has acquired Breath Therapeutics and its subsidiaries for up to €500 million (about $559 million), in a deal that adds a Phase III program to the buyer’s severe respiratory disease pipeline.

German Biotech Breath Therapeutics Acquired in Deal Worth up to €500M

July 25, 2019 - The Italian company Zambon has acquired the German biotech Breath Therapeutics for up to €500M, getting hold of its treatment for a rare lung disease known as popcorn lung.

Italian pharma Zambon takes in Breath Therapeutics through €500M deal

July 25, 2019 - The Italian drugmaker Zambon has bought up Breath Therapeutics, developer of a custom inhaled drug delivery platform, in a deal worth up to €500 million, or about $558.7 million U.S.

Zambon takes a €140m Breath

July 25, 2019 - Breath Therapeutics’ narrow focus on a rare lung disease has paid off. Just over two years after spinning out of the medical device specialist Pari Pharma, Breath has been picked up by Zambon for €140m ($175m) up front.

Pharmakonzern Zambon übernimmt Biotechfirma Breath Therapeutics

July 25, 2019 - Frankfurt Die Münchner Biotechfirma Breath Therapeutics wird italienisch: Nur zwei Jahre nachdem die Münchner aus dem Medtech-Unternehmen Pari ausgegründet wurden, gehen sie an die italienische Zambon-Gruppe verkauft – für bis zu 500 Millionen Euro. (DE)

A 2-year-old fledgling biotech steers into PhIII and nabs a quick $565M buyout deal

July 25, 2019 - A biotech startup in Europe with a very careful focus on a single Phase III therapy has quickly parlayed a drug/device play for a rare lung disease into a $565 million buyout deal.

Exclusive: Breath Therapeutics Launches Phase III Trial to Bring Relief to BOS Patients

April 8, 2019 - In five years it is estimated that about 30,000 people in the United States, Europe and Japan will develop bronchiolitis obliterans syndrome (BOS), which results in respiratory failure and death. But a late-stage treatment under development by Breath Therapeutics could be a possible remedy for this rare and dread disease.

Sign-up for News and Updates from Breath

  • This field is for validation purposes and should be left unchanged.